{"id":"sipv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"sIPV (Sabin inactivated polio vaccine) is a trivalent inactivated vaccine derived from attenuated Sabin poliovirus strains that have been chemically inactivated. It is administered intramuscularly or intradermally to induce humoral and cellular immune responses against all three serotypes of poliovirus, providing protection against poliomyelitis. This vaccine formulation represents an alternative to the standard Salk IPV and is used in immunization programs.","oneSentence":"sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:18.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (poliovirus types 1, 2, and 3)"}]},"trialDetails":[{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT06442449","phase":"PHASE4","title":"Booster Dose of sIPV Co-administered With MMR and HepA-I.","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2024-08-08","conditions":"Poliomyelitis","enrollment":889},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT07297186","phase":"PHASE3","title":"Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2017-08-21","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT05850364","phase":"PHASE3","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-05-22","conditions":"Poliomyelitis, Polio","enrollment":1442},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT06346834","phase":"PHASE4","title":"Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2024-05-20","conditions":"Poliomyelitis","enrollment":200},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT03032588","phase":"PHASE1","title":"A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-10-09","conditions":"Healthy","enrollment":32},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT06460545","phase":"PHASE4","title":"Phase IV Study of Concomitant Administration of the sIPV and HepA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-06-15","conditions":"Polio, Hepatitis A","enrollment":2000},{"nctId":"NCT05386810","phase":"PHASE3","title":"Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-11-05","conditions":"Poliomyelitis","enrollment":1572},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04220515","phase":"PHASE4","title":"Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-02-08","conditions":"Poliomyelitis","enrollment":49731},{"nctId":"NCT04224519","phase":"PHASE4","title":"Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-04-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT04989231","phase":"","title":"An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-09","conditions":"Poliomyelitis","enrollment":450},{"nctId":"NCT04054882","phase":"PHASE4","title":"Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2019-08-16","conditions":"Vaccination","enrollment":702},{"nctId":"NCT04386707","phase":"PHASE3","title":"Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-05-11","conditions":"Poliomyelitis","enrollment":1300},{"nctId":"NCT04638985","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-13","conditions":"Vaccine","enrollment":600},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT04618783","phase":"NA","title":"Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-20","conditions":"Poliomyelitis","enrollment":250},{"nctId":"NCT04264546","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-11-24","conditions":"Polio","enrollment":60},{"nctId":"NCT04264598","phase":"PHASE1","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-08-21","conditions":"Polio","enrollment":100},{"nctId":"NCT03092791","phase":"PHASE1, PHASE2","title":"IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2017-06-07","conditions":"Poliomyelitis","enrollment":340},{"nctId":"NCT03147560","phase":"PHASE4","title":"Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2017-05-02","conditions":"Polio","enrollment":528},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT04053010","phase":"PHASE4","title":"Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2019-08-10","conditions":"Vaccination","enrollment":702},{"nctId":"NCT03902054","phase":"PHASE2","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-12-28","conditions":"Polio and Post-Polio Syndrome","enrollment":600},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03526978","phase":"PHASE3","title":"An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-08-08","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT02985320","phase":"PHASE1, PHASE2","title":"Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2016-10","conditions":"Poliomyelitis","enrollment":708}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":145,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-64152348"],"phase":"marketed","status":"active","brandName":"sIPV","genericName":"sIPV","companyName":"China National Biotec Group Company Limited","companyId":"china-national-biotec-group-company-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3. Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}